Digestive Diseases and Sciences

, Volume 40, Supplement 2, pp 50S–62S | Cite as

Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells

A review and analysis
  • James W. Freston
  • Kurt Borch
  • Stephen J. Brand
  • Enar Carlsson
  • W. Creutzfeldt
  • Rolf Håkanson
  • Lars Olbe
  • Enrico Solcia
  • John H. Walsh
  • M. Michael Wolfe


Since hypochlorhydria can induce hypergastrinemia, and gastrin has a trophic effect on some gastrointestinal cells, states that cause elevated plasma gastrin levels are of interest in terms of effects on cell growth and function. This article reviews the relationship between gastric mucosal cells during periods of acid stimulation and inhibition and analyses the effects of hypochlorhydria and hypergastrinemia on gastric and colonic cells and tumors. Hypochlorhydria releases the inhibitory effect of antral gastrin cells, inducing them to release gastrin in the presence of peptides or amino acids in the gastric lumen or in response to antral distension. Gastrin stimulates the oxyntic mucosa, which may lead to hyperplasia of enterochromaffin-like cells, resulting in enterochromaffin-like carcinoid tumors in aged rats and, rarely, in patients with chronic atrophic gastritis or gastrinomas. In addition to hypergastrinemia, other factors appear to be required for the progression of enterochromaffin-like hyperplasia to carcinoids; genetic factors may be involved. Gastrin elevations due to antisecretory drug therapy are indirectly proportional to the degree of acid inhibition and are reversible upon cessation of therapy. The gastrin levels during omeprazole therapy are similar to those caused by gastric vagotomy. Available evidence does not support a relationship between hypergastrinemia and the occurrence or growth of gastric carcinoma or colonic tumors.

Key Words

omeprazole hypochlorhydria hypergastrinemia enterochromaffin-like cell carcinoids peptic ulcer 


  1. 1.
    Havu N: Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35(suppl 1):42–55, 1986Google Scholar
  2. 2.
    Carney JA, Go VL, Fairbanks VF, Moore SB, Alport EC, Nora FE: The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Intern Med 99:761–766, 1983Google Scholar
  3. 3.
    Borch K, Kenvall H, Liedberg G: Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 88:638–648, 1985Google Scholar
  4. 4.
    Sjöblom SM, Haapiainen R, Miettinen M, Jarvinen H: Gastric carcinoid tumors and atrophic gastritis. Acta Chir Scand 153:37–43, 1987Google Scholar
  5. 5.
    Borch K: Atrophic gastritis and gastric carcinoid tumors. Ann Med 21:291–297, 1989Google Scholar
  6. 6.
    Blair AJ III, Richardson CT, Walsh JH, Feldman M: Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology 92:944–949, 1987Google Scholar
  7. 7.
    Wolfe MM, Soll AH: The physiology of gastric acid secretion. N Engl J Med 319:1707–1715, 1988Google Scholar
  8. 8.
    Lichtenberger LM: Importance of food in the regulation of gastrin release and formation. Am J Physiol 243:G429-G441, 1982Google Scholar
  9. 9.
    Lichtenberger LM, Delansome R, Graziani LA: Importance of amino acid uptake and decarboxylation in gastrin release from isolated G cells. Nature 295:698–700, 1982Google Scholar
  10. 10.
    Wolfe MM, Jain DK, Reel GM, McGuigan JE: Effects of carbachol on gastrin and somatostatin release in rat antral tissue culture. Gastroenterology 87:86–93, 1984Google Scholar
  11. 11.
    Karnik PS, Monahan SJ, Wolfe MM: Inhibition of gastrin gene expression by somatostatin. J Clin Invest 83:367–372, 1989Google Scholar
  12. 12.
    Karnik PS, Wolfe MM: Somatostatin stimulates gastrin mRNA turnover in dog antral mucosa. J Biol Chem 265:2550–2555, 1990Google Scholar
  13. 13.
    Brand SJ, Stone D: Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria. J Clin Invest 82:1059–1066, 1988Google Scholar
  14. 14.
    Schubert ML, Edwards NF, Arimura A, Makhlouf GM: Paracrine regulation of gastric acid secretion by fundic somatostatin. Am J Physiol 252:G485-G490, 1987Google Scholar
  15. 15.
    Schubert ML, Edwards NF, Makhlouf GM: Regulation of gastric somatostatin secretion in the mouse by luminal acidity: A local feedback mechanism. Gastroenterology 94:317–322, 1988Google Scholar
  16. 16.
    Short GM, Doyle JW, Wolfe MM: Effect of antibodies to somatostatin on acid secretion and gastrin release by the isolated perfused rat stomach. Gastroenterology 88:984–988, 1985Google Scholar
  17. 17.
    Park J, Chiba T, Yamada T: Mechanisms for direct inhibition of canine gastric parietal cells by somatostatin. J Biol Chem 262:14190–14196, 1987Google Scholar
  18. 18.
    Nylander O, Bergqvist E, Öbrink KJ: Dual inhibitory actions of somatostatin on isolated gastric glands. Acta Physiol Scand 125:111–119, 1985Google Scholar
  19. 19.
    Chiba T, Taminato T, Kadowaki S, Abe H, Chihara K, Seino Y, Matsukura S, Fujita T. Effects of glucagon, secretin, and vasoactive intestinal polypeptide on gastric somatostatin and gastrin release from isolated perfused rat stomach. Gastroenterology 79:67–71, 1980Google Scholar
  20. 20.
    Wolfe MM, Reel GM, McGuigan JE: Inhibition of gastrin release by secretin is mediated by somatostatin in cultured rat antral mucosa. J Clin Invest 72:1586–1593, 1983Google Scholar
  21. 21.
    Makhlouf GM, Schubert ML: Gastric somatostatin: a paracrine regulator of acid secretion. Metabolism 39:138–142, 1990Google Scholar
  22. 22.
    Soll AH, Amirian DA, Thomas LP, Reedy TJ, Elashoff JD: Gastrin receptors on isolated canine parietal cells. J Clin Invest 73:1434–1447, 1984Google Scholar
  23. 23.
    Kleveland PM, Waldum HL, Larsson H: Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not, augment maximal histamine-stimulated acid secretion. Scand J Gastroenterol 22:705–713, 1987Google Scholar
  24. 24.
    Soll AH: Secretagogue stimulation of [14C] aminopyrine accumulation by isolated canine parietal cells. Am J Physiol 238:G366-G375, 1980Google Scholar
  25. 25.
    Feldman M: Inhibition of gastric acid secretion by selective and nonselective anticholinergics. Gastroenterology 86:361–366, 1984Google Scholar
  26. 26.
    Refern JS, Thirlby M, Feldman M, Richardson CT: Effect of pentagastrin on gastric mucosal histamine in dogs. Am J Physiol 248:G369-G375, 1985Google Scholar
  27. 27.
    Soll AH, Toomey M, Culp D, Shanahan F, Beaven MA: Modulation of histamine release from canine mucosal mast cells. Am J Physiol 254:G40-G48, 1988Google Scholar
  28. 28.
    Soll AH, Berglindh T: Physiology of isolated gastric glands and parietal cells: Receptor and effectors regulating function.In Physiology of the Gastrointestinal Tract, Vol 1, 2nd ed. Johnson LR, (ed). New York, Raven Press, pp 883–909, 1987Google Scholar
  29. 29.
    Chen MC, Amirian DA, Toomey M, Sanders MJ, Soll AH: Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase. Gastroenterology 94:1121–1129, 1988Google Scholar
  30. 30.
    Håkanson R, Sundler F: Do histamine-storing cells in the gastric mucosa mediate the acid-stimulating action of gastrin? Handb Exp Pharmacol 97:325–346, 1991Google Scholar
  31. 31.
    Håkanson R, Böttcher G, Ekblad E, Panula P, Simonsson M, Dohlsten M, Hallberg T, Sundler F: Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry 86:5–17, 1986Google Scholar
  32. 32.
    Håkanson R, Böttcher G, Sundler F, Vallgren S: Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion 35:23–41, 1986Google Scholar
  33. 33.
    Cattan D, Roucayrol A-M, Launay J-M, Callebert J, Charasz N, Nunt Y, Belaiche J, Kalifat R: Circulating gastrin, endocrine cells, histamine content and histidine decarboxylase activity in atrophic gastritis. Gastroenterology 97:586–596, 1989Google Scholar
  34. 34.
    Nakata H, Matsui T, Ito M, Taniguchi T, Naribayashi Y, Arina N, Nakamura A, Kinoshita Y, Chihara K, Hosoda S, Chiba T: Cloning and characterization of gastrin receptor from ECL cell carcinoid tumour ofMastomys natalensis. Biochem Biophys Res Commun 187:1151–1157, 1992Google Scholar
  35. 35.
    Inomoto Y, Kinoshita Y, Nakamura A, Arima N, Yamashita Y, Nakata H, Yamamura Y, Hosoda S, Chiba T: Characterization of gastrin/CCK receptors on gastric carcinoid tumour membrane ofMastomys natalensis. Regul Pept 43:149–158, 1993Google Scholar
  36. 36.
    Sandvik AK, Waldum HL: CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. Am J Physiol 260:G925-G928, 1991Google Scholar
  37. 37.
    Sandvik AK, Kleveland PM, Waldum HL: Muscarinic M2 stimulation releases in the totally isolated, vascularly perfused rat stomach. Scand J Gastroenterol 23:1049–1056, 1988Google Scholar
  38. 38.
    Gerber JG, Payne NA: The role of gastric secretagogues in regulating gastric histamine releasein vivo. Gastroenterology 102:403–408, 1992Google Scholar
  39. 39.
    Lehy T, Dubrasquet M, Bonfils S: Effect of somatostatin on normal and gastrin stimulated cell proliferation in the gastric and intestinal mucosae of the rat. Digestion 19:99–109, 1979Google Scholar
  40. 40.
    Olsen PS, Poulsen SS, Therkelsen K, Nexo E. Oral administration of synthetic human urogastrone promotes healing of chronic duodenal ulcers in rats. Gastroenterology 90: 911–917 1986Google Scholar
  41. 41.
    Rhodes JA, Tam JP, Finke U, Saunders M, Bernanke J, Silen M, Murphy RA: Transforming growth factor alpha inhibits secretion of gastric acid. Proc Natl Acad Sci USA 83:3844–3846, 1986Google Scholar
  42. 42.
    Koyama S-Y, Podolsky DK: Differential expression of transforming growth factors alpha and beta in rat intestinal epithelial cells. J Clin Invest 83:1768–1773, 1989Google Scholar
  43. 43.
    Brand SJ, Merchant J, Baackwich D: Stimulation of gastrin gene transcription of epidermal growth factor/TGF and inhibition by somatostatin-feedforward and feedback controls on gastrin synthesis to prevent mucosal ulceration by gastric acid secretion.In The Stomach as an Endocrine Organ. Håkanson R, Sundler F (eds). Amsterdam, Elsevier, pp 233–249, 1991Google Scholar
  44. 44.
    Johnson LR: New aspects in the trophic action of gastrointestinal hormones. Gastroenterology 72:788–792, 1977Google Scholar
  45. 45.
    Polk WH, Saroka CJ, Goldenring J, Modlin IM, Bundz S, Dempsey PJ, Coffey RJ. Immunolocalization of transforming growth factor alpha (TGF) and its receptor to the parietal cell in normal gastrin mucosa. Gastroenterology 100:A660, 1991Google Scholar
  46. 46.
    Beauchamp RD, Bernard JA, McCutchen CM, Cherner JA, Coffey RJ Jr: Localization of transforming growth factor A and its receptor in gastric mucosal cells. J Clin Invest 84:1017–1023, 1989Google Scholar
  47. 47.
    Malden LT, Novak U, Burgess AW: Expression of transforming growth factor alpha messenger RNA in the normal and neoplastic gastrointestinal tract. Int J Cancer 43:380–384, 1989Google Scholar
  48. 48.
    Wright NA, Pike C, Elia G: Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature 343:82–85, 1990Google Scholar
  49. 49.
    Chen MC, Lee AT, Soll AS: Mitogenic response of canine fundic epithelial cells in short-term culture to transforming growth factor α and insulin-like growth factor 1. J Clin Invest 87:1716–1723, 1991Google Scholar
  50. 50.
    Schonbrunn A, Krasnoff M, Westendorf JM, Tashjian AH: Epidermal growth factor and thyrotropin-releasing hormone act similarly on a clonal pituitary strain. J Cell Biol 85:786–797, 1980Google Scholar
  51. 51.
    Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC: Overexpression of TGFs in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61:1121–1135, 1990Google Scholar
  52. 52.
    Korc M, Chandrasekar B, Freiss H, Buchler M, Kumar S: Immunohistochemical and molecular evidence for the production of transforming growth factor alpha in normal and cancerous human pancreas. Gastroenterology 100:A281, 1991Google Scholar
  53. 53.
    Godley JM, Brand SJ: Regulation of the gastrin promoter by epidermal growth factor and neuropeptides. Proc Natl Acad Sci USA 86:3036–3040, 1989Google Scholar
  54. 54.
    Bachwich D, Merchant J, Brand SJ: Identification of acis regulatory element mediating somatostatin inhibition of EGF-stimulated gastrin gene transcription. Mol Endocrinol 6:1175–84, 1992Google Scholar
  55. 55.
    Oscarson J, Håkanson R, Liedberg G, Lundquist O, Sundler F, Thorell J: Variated serum gastrin concentration: trophic effects on the gastrointestinal tract of the rat. Acta Physiol Scand 475(suppl):3–27, 1979Google Scholar
  56. 56.
    Håkanson R, Blom H, Carlsson E, Larsson H, Ryberg B, Sundler F: Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regul Pept 13:225–233, 1986Google Scholar
  57. 57.
    Ryberg B, Axelson J, Håkanson R, Sundler F, Mattsson H: Trophic effects of continuous infusion of (Leu15)-gastrin-17 in the rat. Gastroenterology 98:33–38, 1990Google Scholar
  58. 58.
    Håkanson R, Axelson J, Ekman R, Sundler F: Hypergastrinaemia evoked by omeprazole stimulates growth of gastric mucosa but not of pancreas or intestines in hamster, guinea pig and chicken. Regul Pept 23:105–115, 1988Google Scholar
  59. 59.
    Johnson LR. Regulation of gastrointestinal growth.In Physiology of the Gastrointestinal Tract. Johnson LR (ed). New York, Raven Press, pp 301–334, 1987Google Scholar
  60. 60.
    Solomon T: Trophic effect of pentagastrin on gastrointestinal in fed and fasted rats. Gastroenterology 91:108–116, 1986Google Scholar
  61. 61.
    Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C: Toxicological studies on omeprazole. Scand J Gastroenterol 108(suppl):53–69, 1985Google Scholar
  62. 62.
    Borch K, Penvall H, Liedberg G, Andersen BH: Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 21:357–363, 1986Google Scholar
  63. 63.
    Håkanson R, Ekeland M, Sundler F: Activation and proliferation of gastric endocrine cells.In Evolution and Tumour Pathology of the Neuroendocrine System. Fernstrom Foundation Series. Falkmer S, Hakanson R, Sundler F (eds). Amsterdam, Elsevier, pp 371–398, 1984Google Scholar
  64. 64.
    Creutzfeldt W, Stockman F, Conlon JM, Folsch UR, Bonatz G, Wulfrath M: Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion 35(suppl 1):84–97, 1986Google Scholar
  65. 65.
    Mattsson H, Havu N, Bräutigam J, Carlsson K, Lundell L, Carlsson E: Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 100:311–319, 1991Google Scholar
  66. 66.
    Carlsson E: A review of the effects of long-term acid inhibition tion in animals. Scand J Gastroenterol 166(suppl):19–23, 1989Google Scholar
  67. 67.
    Hirschowitz BI, Griffith J, Pellegrin D, Cumming OW: Rapid regression of ECL-cell gastric carcinoids in 3 patients with pernicious anemia after elimination of hypergastrinemia by antrectomy. Gastroenterology 98:A286, 1990Google Scholar
  68. 68.
    Majka JA, Sher S: Spontaneous gastric carcinoid tumor in an aged Sprague-Dawley rat. Vet Pathol USA 26:88–90, 1989Google Scholar
  69. 69.
    Havu N, Mattsson H, Ekman N, Carlsson E: Enterochromaffin-like carcinoids in the rat gastric mucosa following longterm administration of ranitidine. Digestion 45:189–195, 1990Google Scholar
  70. 70.
    Eason CT, Pattison A, Howells DD, Bonner FW: The effect of ciprofibrate on gastric secretion in the rat. J Pharm Pharmacol 40:512–513, 1988Google Scholar
  71. 71.
    Lee AK, DeLellis RA, Blount M, Nunnemacher G, Wolfe HJ: Pituitary proliferative lesions in aging male Long-Evans rats. A model of mixed multiple endocrine neoplasia syndrome. Lab Invest 47:595–602, 1982Google Scholar
  72. 72.
    Creutzfeldt W, Lamberts R, Stockmann F, Brunner G: Quantitative studies of gastric endocrine cells in patients receiving long-term treatment with omeprazole. Scand J Gastroenterol 166(suppl):122–128, 1989Google Scholar
  73. 73.
    Walsh JH, Lam SK: Physiology and pathology of gastrin. Clin Gastroenterol 9:567–591, 1980Google Scholar
  74. 74.
    Feldman M, Corbette DB, Ramsey EJ, Walsh JH, Richardson CT: Abnormal gastric function in longstanding, insulindependent diabetic patients. Gastroenterology 77:12–17, 1979Google Scholar
  75. 75.
    Creutzfeldt W: The achlorhydria-carcinoid sequence: Role of gastrin, Digestion 39:61–79, 1988Google Scholar
  76. 76.
    Mitchell CJ, Jewell DP, Lewin MR, McLaughlin JE, Moorhead JF: Gastric function and histology in chronic renal failure. J Clin Pathol 32:208–213, 1979Google Scholar
  77. 77.
    Ala-Kaila K, Kekki M, Paronen I, Paakkala T: Serum gastrin in chronic renal failure: Its relation to acid secretion, G-cell density, and upper gastrointestinal findings. Scand J Gastroenterol 24:939–948, 1989Google Scholar
  78. 78.
    Lam SK. Hypergastrinaemia in cirrhosis of liver. Gut 17:700–708, 1976Google Scholar
  79. 79.
    Walsh JH, Grossman MI: Gastrin N Engl J Med 292:1324–1332, 1975Google Scholar
  80. 80.
    Mayer G, Arnold R, Feurle G, Fuchs K, Ketterer H, Track NS, Creutzfeldt W: Influence of feeding and sham feeding upon serum gastrin and gastric acid secretion in control subjects and duodenal ulcer patients. Scand J Gastroenterol 9:703–710, 1974Google Scholar
  81. 81.
    Walsh JH, Richardson CT, Fordtran JS: pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest 55:462–468, 1975Google Scholar
  82. 82.
    Karnes WE, Ohning GV, Sytnik B, Kim SWR, Walsh JH: Elevation of meal-stimulated gastrin release in subjects withHelicobacter pylori infection: Reversal by low intragastric pH. Rev Infect Dis 13:S665-S670, 1991Google Scholar
  83. 83.
    Levi S, Beardshall K, Haddad G, Playford R, Ghosh P, Calam J:Campylobacter pylori and duodenal ulcers: The gastrin link. Lancet 1:1167–1168, 1989Google Scholar
  84. 84.
    Graham DY, Opekun A, Lew GM, Evans DJ Jr, Klein PD, Evans DG: Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance ofHelicobacter (Campylobacter) pylori infection. Am J Gastroenterol 85:394–398, 1990Google Scholar
  85. 85.
    Smith JT, Pounder RE, Nwokolo CU, Lanzon-Miller S, Evans DG, Graham DY, Evans DJ Jr: Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected withHelicobacter pylori, Gut 31:522–525, 1990Google Scholar
  86. 86.
    Trudeau WL, McGuigan JE: Relations between serum gastrin levels and rates of gastric hydrochloric acid secretion. N Engl J Med 284:408–412, 1971Google Scholar
  87. 87.
    Ganguli PC, Cullen DR, Irvine WJ: Radioimmunoassay of plasma-gastrin in pernicious anaemia, achlorhydria without pernicious anaemia, hypochlorhydria, and in controls. Lancet 1:155–158, 1971Google Scholar
  88. 88.
    Creutzfeldt W, Arnold R, Creutzfeldt C, Feurle G, Ketterer H: Gastrin and G-cells in the antral mucosa of patients with pernicious anaemia, acromegaly and hyperparathyroidism and in a Zollinger-Ellison tumour of the pancreas. Eur J Clin Invest 1:461–479, 1971Google Scholar
  89. 89.
    Lam SK, Chan PKW, Wong J, Ong GB: Fasting and postprandial serum gastrin levels before and after highly selective gastric vagotomy, truncal vagotomy with pyloroplasty and truncal vagotomy with antrectomy: Is there a cholinergic antral gastrin inhibitory and releasing mechanism? Br J Surg 65:797–800, 1978Google Scholar
  90. 90.
    Feldman M, Richardson CT, Taylor IL, Walsh JH: Effect of atropine on vagal release of gastrin and pancreatic polypeptide. J Clin Invest 63:294–298, 1979Google Scholar
  91. 91.
    Lind T, Cederberg C, Olausson M, Olbe L: 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology 99:1593–1598, 1990Google Scholar
  92. 92.
    Brunner G, Creutzfeldt W, Harke U, Lamberts R: Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion 39:80–90, 1988Google Scholar
  93. 93.
    Lundell L, Lindstedt G, Olbe L: Origin of gastrin liberated by gastrin releasing peptide in man. Gut 28:1128–1133, 1987Google Scholar
  94. 94.
    Suzuki H, Matsumoto K, Terashima H: Serum levels of gastrin in patients with colorectal neoplasia. Dis Colon Rectum 31:716–717, 1988Google Scholar
  95. 95.
    Smith JP, Wood JG, Solomon TE: Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci 34:171–174, 1989Google Scholar
  96. 96.
    Seitz J-F, Giovanni M, Gourvernet J, Gauthier AP: Elevated serum gastrin levels in patients with colorectal neoplasia. J Clin Gastroenterol 13:541–545, 1991Google Scholar
  97. 97.
    Creutzfeldt W, Lamberts R: Is hypergastrinaemia dangerous to man? Scand J Gastroenterol 180(suppl):179–191 1991Google Scholar
  98. 98.
    Kaufmann HP, Ottenjann R: Serum-Nuchtern-Gastrin-Werte bei Kolonadenomen und Kolorektalen Karzinomen. Z Gastroenterol 29:527–528, 1991Google Scholar
  99. 99.
    Feurle GE: Effect of rising intragastric pH induced by several antacids on serum gastrin concentrations in duodenal ulcer patients and in a control group. Gastroenterology 68:1–7, 1975Google Scholar
  100. 100.
    Behar J, Hitching M, Smyth RD: Calcium stimulation of gastrin and gastric acid secretion: Effect of small doses of calcium carbonate. Gut 18:442–448, 1977Google Scholar
  101. 101.
    Peterson WL, Walsh JH, Richardson CT: Cimetidine blocks antacid-induced hypergastrinemia. Gastroenterology 90:48–52, 1986Google Scholar
  102. 102.
    Sjövall M, Lindstedt G, Olbe L, Lundell L: Effect of parietal cell vagotomy and cholinergic blockade on gastrin release in man induced by gastrin-releasing peptide. Digestion 46:114–120, 1990Google Scholar
  103. 103.
    Lazzaroni M, Sangaletti O, Del Soldato P, Bianchi Porro G: Effect of pirenzepine and atropine on peptone mealstimulated gastric secretion and plasma gastrin in healthy volunteers, patients with duodenal ulcer and vagotomized patients. Digestion 32:267–272, 1985Google Scholar
  104. 104.
    Ippoliti AF, Isenberg JI, Hagie L: Effect of oral and intravenous 16, 16-dimethyl prostaglandin E2 in duodenal ulcer and Zollinger-Ellison syndrome patients. Gastroenterology 80:55–59, 1981Google Scholar
  105. 105.
    Mahachai V, Walker K, Sevelius H, Thomson AB: Antisecretory and serum gastrin lowering effect of enprostil in patients with duodenal ulcer disease. Gastroenterology 89:555–561, 1985Google Scholar
  106. 106.
    Lanzon-Miller S, Allison MC, Pounder RE, Ball S, Hamilton MR, Chronos NAF: Enprostil inhibits post-prandial gastrin release: A dose-response study. Aliment Pharmacol Ther 2:317–323, 1988Google Scholar
  107. 107.
    Befrits R, Uvnäs-Moberg K, Johansson C: Interactions between antral peptides and prostaglandin biosynthesis in gastric acid regulation in man. Digestion 45:9–18, 1990Google Scholar
  108. 108.
    Gavey CJ, Smith JT, Nwokolo CU, Pounder RE: Clofibrate raises human 24 h intragastric acidity but does not affect plasma gastrin concentration. Br J Clin Pharmacol 29:473–477, 1990Google Scholar
  109. 109.
    Smout AJ, Bogaard JW, van Hattum J, Akkermans LM: Effects of cimetidine and ranitidine on interdigestive and postprandial lower esophageal sphincter pressures and plasma gastrin levels in normal subjects. Gastroenterology 88:557–563, 1985Google Scholar
  110. 110.
    Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NAF, Raymond F, Olausson M, Cederberg C: Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1:239–251, 1987Google Scholar
  111. 111.
    Lanzon-Miller S, Pounder RE, Ball SG, Dalgleish DJ, Coward J, Jackson AO: The effects of famotidine, 40 mg at night, on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Scand J Gastroenterol 23:244–250, 1988Google Scholar
  112. 112.
    Smith JT, Pounder RE: Sufotidine 600 mg bd virtually eliminates 24 hour intragastric acidity in duodenal ulcer subjects. Gut 31:291–293, 1990Google Scholar
  113. 113.
    Brunner G, Creutzfeldt W, Harke U, Lamberts R: Efficacy and safety of long term treatment with omeprazole in patients with acid related diseases resistant to ranitidine. Can J Gastroenterol 3(suppl A):72A-76A, 1989Google Scholar
  114. 114.
    Brunner G, Creutzfeldt W: Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol 166(suppl):101–105, 1989Google Scholar
  115. 115.
    Jansen JBMJ, Klinkenberg-Knol EC, Meuwissen SGM, De Bruijne JW, Festen HPM, Snel P, Lückers AEG, Biemond I, Lamers CBHW: Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 99:621–628, 1990Google Scholar
  116. 116.
    Festen HP, Tuynman HA, Défize J, Pals G, Frants RR, Straub JP, Meuwissen SG: Effect of single and repeated doses of omeprazole on gastric acid and pepsin secretion and fasting serum gastrin and serum pepsinogen I levels. Dig Dis Sci 31:561–566, 1986Google Scholar
  117. 117.
    Sharma B, Axelson M, Pounder RP, Lundborg P, Öhman M, Santana A, Talbot M, Cederberg C: Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1:67–76, 1987Google Scholar
  118. 118.
    Karnes WE, Berlin RG, Maxwell V, Sytnik B, Root JK, Walsh JH Prolonged inhibition of acid secretion causes hypergas-trinemia without altering pH inhibition of gastrin release in humans Aliment Pharmacol Ther 4:443–456, 1990Google Scholar
  119. 119.
    Walsh JH, Sytnik B, Maxwell V, Chew P, Karnes W, Lu S, Randall G, Reedy TJ, Root J, Lengericha R, Berlin R: Reversibility of plasma changes induced by omeprazole or ranitidine in man. Am J Gastroenterol 85:1042, 1988Google Scholar
  120. 120.
    Pounder R, Smith J: Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 19:141–153, 1990Google Scholar
  121. 121.
    Koop H, Naumann-Koch C, Arnold R: Effect of omeprazole on serum gastrin levels: influence of age and sex. Gastroenterology 28:603–605, 1990Google Scholar
  122. 122.
    Brunner GHG, Lamberts R, Creutzfeldt W: Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion 47(suppl 1):64–68, 1990Google Scholar
  123. 123.
    Borch K: Epidemiologic, clinicopathologic, and economic aspects of gastroscopic screening of patients with pernicious anemia. Scand J Gastroenterol 21:21–30, 1986Google Scholar
  124. 124.
    Roucayrol AM, Cattan D: Evolution of funcid argyrophil cell hyperplasia in nonantral atrophic gastritis. Gastroenterology 99:1307–1314, 1990Google Scholar
  125. 125.
    Solcia E, Capella C, Fiocca R, Rindi G, Rosai J: Gastric argyrophil carcinoidosis in patients with Zollinger Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 14:503–513, 1990Google Scholar
  126. 126.
    Jensen RT, Dippman JL, Gardner JD: Gastrinoma.In The Exocrine Pancreas: Biology, Pathobiology and Diseases. Go VLW (ed). New York, Raven Press, pp 727–744, 1986Google Scholar
  127. 127.
    Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, Grimelius L, Havu N: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41:185–200, 1988Google Scholar
  128. 128.
    Maton PN, Lack EE, Collen MJ, Cornelius MJ, David E, Gardner JD, Jensen RT: The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 99:943–950, 1990Google Scholar
  129. 129.
    Poynter D, Pick CR, Harcourt RA, Selway SAM, Ainge G, Harman IW, Spurling NW, Fluck PA, Cook JL. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumors in the rat. Gut 26:1284–1295, 1985Google Scholar
  130. 130.
    Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study. Gastroenterology 104:994–1006, 1993Google Scholar
  131. 131.
    Kekki M, Siurala M, Varis K, Sipponen P, Sistonen P, Nevanlinna RH: Classification principles and genetics of chronic gastritis. Scand J Gastroenterol 141(suppl):1–28, 1987Google Scholar
  132. 132.
    Lamberts R, Creutzfeld W, Strüber HG, Brunner G, Solcia E: Long-term omeprazole therapy in peptid ulcer disease. Gastrin, endocrine cell growth and gastritis. Gastroenterology 104:1356–1370, 1993Google Scholar
  133. 133.
    Maaroos HI, Salupere V, Uibo R, Kekki M, Sipponen P: Seven-year follow-up study of chronic gastritis in gastric ulcer patients. Scand J Gastroenterol 20:198–204, 1985Google Scholar
  134. 134.
    Havu N, Maaroos HI, Sipponen I: Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol 26(suppl 186):90–92, 1991Google Scholar
  135. 135.
    Lamers CBHW, Jansen JBMJ: Role of gastrin and cholecys-tokinin in tumors of the gastrointestinal tract. Eur J Cancer Clin Oncol 2:267–273, 1988Google Scholar
  136. 136.
    Morris DL, Watson SA, Durrant LG, Harrison JD: Hormonal control of gastric and colorectal cancer in man. Gut 30:425–429, 1989Google Scholar
  137. 137.
    Freston JW: Clinical significance of hypergastrinemia: Relevance to gastrin monitoring during omeprazole therapy. Digestion 51:(suppl 1)102–114, 1992Google Scholar
  138. 138.
    Rae-Venter B, Townsend CM Jr, Thompson JC, Simon PM: Gastrin receptors in human colon carcinoma. Gastroenterology 80:A1256, 1981Google Scholar
  139. 139.
    Singh P, Rae-Venter B, Townsend CM Jr, Khalil T, Thompson C: Gastrin receptors in normal and malignant gastrointestinal mucosa: Age-associated changes. Am J Physiol 249:G761-G769, 1985Google Scholar
  140. 140.
    Elsborg L, Mosbech J: Pernicious anaemia as a risk factor in gastric cancer. Acta Med Scand 206:315–318, 1979Google Scholar
  141. 141.
    Svendsen JH, Dahl C, Svendsen LB, Christiansen PM: Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand J Gastroenterol 21:16–20, 1986Google Scholar
  142. 142.
    Takahashi T, Yamagushi T, Bando K: Effects of gastrointestinal hormones on protein synthesis and growth of gastrointestinal cancers. Int Cancer Congress 97:42 (abstract) 1982Google Scholar
  143. 143.
    Tahara E, Haizuka S: Effect of gastroenteropancreatic endocrine hormones on the histogenesis of gastric cancer in rats induced by N-methyl-N-nitro-nitroguanidine: with special reference to development of scirrhous gastric cancer. Gann 66:421–426, 1975Google Scholar
  144. 144.
    Tatsuta M, Ito HT, Okuda S, Taniguchi H, Tamura H: Effect of prolonged administration of gastrin on experimental carcinogenesis in rat stomach induced byN-methyl-N-nitro-N-nitrosoguanidine. Cancer Res 37:1808–1810, 1977Google Scholar
  145. 145.
    Carter DC: Cancer after peptic ulcer surgery. Gut 28:921–923, 1987Google Scholar
  146. 146.
    Caygill CPJ, Hill MJ, Kirkham JS, Northfield TC: Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet 1:929–931, 1986Google Scholar
  147. 147.
    Chicoine L, Guo Y-S, Thompson JC, Townsend CMJR, Singh P: Differences in the molecular size of gastrin receptors (GR) on normal and cancerous gut tissues from mice. Gastroenterology 94:A67, 1988Google Scholar
  148. 148.
    Thompson JC, Greenley GH Jr, Rayford PL, Townsend CM Jr: Gastrointestinal Endocrinology. New York, McGraw-Hill, 1987Google Scholar
  149. 149.
    Karlin DA, McBath M, Jones RD, Elwyn KE, Romsdahl MM: Hypergastrinemia and colorectal carcinogenesis in the rat. Cancer Lett 29:73–78, 1985Google Scholar
  150. 150.
    Tatsuta M, Yamamura H, Ichii M, Taniguchi H: Effect of prolonged administration of gastrin on experimental carcinogenesis in rat colon induced by intrarectal instillation ofN-methyl-N-nitrosoguanidine. Cancer Res 43:2258–2260, 1983Google Scholar
  151. 151.
    Tatsuta M, Yamamura H, Iishi H, Noguchi S, Ichii M, Taniguchi H: Gastrin has no promoting effect on chemically induced colonic tumors in Wistar rats. Eur J Cancer Clin Oncol 21:741–744, 1985Google Scholar
  152. 152.
    Talley NJ, Chute CG, Larson DE, Epstein R, Lydick EG, Melton LJ: Risk for colorectal adenocarcinoma in pernicious anemia. A population-based cohort study. Ann Intern Med 111:738–742, 1989Google Scholar
  153. 153.
    Brinton LA, Gridley G, Hrubec Z, Hoover R, Fraimeni JF Jr: Cancer risk following pernicious anemia. Br J Cancer 59:810–813, 1989Google Scholar
  154. 154.
    Siurla M, Lehtola J, Ihamaki T: Atrophic gastritis and its sequelae. Results of 19–23 years' follow-up examinations. Scand J Gastroenterol 9:441–446, 1974Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • James W. Freston
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • Kurt Borch
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • Stephen J. Brand
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • Enar Carlsson
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • W. Creutzfeldt
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • Rolf Håkanson
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • Lars Olbe
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • Enrico Solcia
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • John H. Walsh
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  • M. Michael Wolfe
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
  1. 1.Department of MedicineUniversity of Connecticut Health CenterFarmingtonUSA
  2. 2.Department of SurgeryUniversity Hospital of LinköpingLinköpingSweden
  3. 3.Gastrointestinal UnitMassachusetts General HospitalBostonUSA
  4. 4.Astra Hässle ABMölndalSweden
  5. 5.Division of Gastroenterology and EndocrinologyUniversity of GöttingenGöttingenGermany
  6. 6.Department of PharmacologyUniversity of LundLundSweden
  7. 7.Department of Surgery IISahlgrenska HospitalGöteborgSweden
  8. 8.Department of Human PathologyUniversity of PaviaPaviaItaly
  9. 9.UCLA Medical SchoolVA WadsworthLos AngelesUSA
  10. 10.Gastroenterology DivisionBrigham and Women's Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations